Fiduciary Alliance’s CASI Pharmaceuticals CASI Stock Holding History

Fiduciary Alliance’s Portfolio CASI Stock Details CASI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-30	Closed	-$75	–	275
2023 Q2	$75	Buy	+30	New	+$81	﹤0.01%	989

Other funds holding CASI

WSCM

Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return

WSC

Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Fiduciary Alliance's CASI Position: Q3 2023 in Review

Fiduciary Alliance sold out of CASI Pharmaceuticals (CASI) in Q3 2023, closing a stake of 30 shares — an estimated $75 sold.

Fiduciary Alliance first reported a position in CASI in Q2 2023 and held it in 1 quarter. The position peaked at $75 in Q2 2023. 19 funds tracked by Wall St. Rank hold CASI as of Q3 2023.

Fiduciary Alliance reported no remaining CASI Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Fiduciary Alliance sold 30 CASI Pharmaceuticals shares in Q3 2023, an estimated $75.
Fiduciary Alliance first reported a position in CASI Pharmaceuticals in Q2 2023 and held it in 1 quarter.
Fiduciary Alliance's CASI Pharmaceuticals position peaked at $75 in Q2 2023.
19 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2023.

Based on Fiduciary Alliance's 13F filing for Q3 2023, filed 18 Oct 2023.